Early Onset Preeclampsia:
One of the Remaining
Great Challenges in
Obstetrics

Early onset preeclampsia (EOPE) is defined as preeclampsia resulting in the delivery of the fetus before 34 weeks’ gestation. EOPE contributes more to the morbidity and mortality of pregnant mothers and babies than the more frequent late onset form. EOPE is a more commonly occurring condition than Down syndrome.

Early risk assessment of EOPE allows a valuable window of opportunity for education, increased monitoring and prophylactic intervention, including low-dose aspirin, to significantly decrease the severity and/or incidence of the disease.

PreeclampsiaScreenSM | T1: Earlier Insight Means More Opportunity

PreeclampsiaScreenSM | T1 is a first-of-its-kind serum screening test that analyzes three biochemical markers in the mother’s blood: PAPP-A (pregnancy-associated plasma protein-A), PlGF (placental growth factor) and AFP (alpha fetoprotein). Together, these three biochemical markers can contribute to accurate prediction of risk for early onset preeclampsia in the first-trimester.

Test Specifications for PreeclampsiaScreenSM | T1

Biochemistry + History Biochemistry + History + MAP Biochemistry + History + UtAD-PI Biochemistry + History + MAP + UtAD-PI
Markers PIGF, PAPP-A, AFP PIGF, PAPP-A, AFP, MAP PIGF, PAPP-A, UtAD-PI PIGF, PAPP-A, AFP, MAP, UtAD-PI
Gestational Age
(ultrasound dated)
10 weeks, 0 days-
13 weeks, 6 days
11 weeks, 1 day-
13 weeks, 6 days
11 weeks, 1 day-
13 weeks, 6 days
11 weeks, 1 day-
13 weeks, 6 days
Detection Rate at 5% FPR 60% 77% 82% 91%
Requirements
  • 5 ml maternal serum in SST(red/grey speckled or gold) tube or red top tube
  • 5 ml maternal serum in SST tube or red top tube
  • Left arm, right arm blood pressure
  • 5 ml maternal serum in SST tube or red top tube
  • UtAD-PI measurement
  • 5 ml maternal serum in SST tube or red top tube
  • MAP
  • UtAD-PI measurement
TAT 24-48 hours 24-48 hours 24-48 hours 24-48 hours

MAP = mean arterial pressure; UtAD-PI = uterine artery Doppler pulsatility index

Did you know? The American Congress of Obstetricians and Gynecologists and the Preeclampsia Foundation recently endorsed bipartisan legislation to strengthen state efforts to prevent maternal deaths. The Preventing Maternal Deaths Act will support states in establishing or expanding their mortality review efforts.

Early Preeclampsia Screening Improves Clinical Focus

Know who is at risk before symptoms develop and have high confidence in a negative result, with PreeclampsiaScreenSM | T1.* Utilizing the full protocol, including MAP and UtAD-PI, the sensitivity is 91%, the specificity is 95%, the PPV is 1 in 9.5 and the NPV is 99.94%.

In 2,000 pregnancies, 10 cases of EOPE are expected
Screening Detected EOPE Cases
No screening
Maternal History
Preeclampsia Screen T1: Biochemistry
Preeclampsia Screen T1: Biochemistry +
Mean Arterial Pressure(MAP)
Preeclampsia Screen T1: Biochemistry + MAP + UtAD

*False positive rates are representative of a general screening population. Rates may vary depending on history. Risk cutoff in each case is 1 in 50.


For more information about Maternal Fetal ScreenSM | T1, or to order supplies, please contact your local Genetics Account Executive, or call us at 1-888-NTD-LABS.

DISCLAIMER: This test is a part of a lab service offering provided by Eurofins NTD, LLC. This test was developed and its performance characteristics determined by Eurofins NTD, LLC. It has not been cleared or approved by the U.S. Food and Drug Administration. The methods and performance characteristics have been reviewed and approved by the New York State Department of Health. The test results do not eliminate the possibility that this pregnancy may be associated with birth defects or pregnancy complications including preeclampsia, pre-term delivery and low birth weight. The multiple of the median and risk results provided in the test report are dependent on the accuracy of the demographic and ultrasound information provided. The ordering physician should ensure that the ultrasound information has been obtained from a sonographer who is credentialed by and participating in a uterine artery Doppler quality review program such as FMF. Eurofins NTD, LLC. assumes no responsibility for ensuring that the ultrasound information has been obtained by a properly credentialed sonographer, including verification or updates to credentialing status.